AIM ImmunoTech (NYSE:AIM) and Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey

Monte Rosa Therapeutics (NASDAQ:GLUE) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares Monte Rosa Therapeutics and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	N/A	-74.13%	-49.14%
AIM ImmunoTech	-16,123.32%	-191.38%	-128.26%

Institutional & Insider Ownership

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Monte Rosa Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Monte Rosa Therapeutics and AIM ImmunoTech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	0	1	2	0	2.67
AIM ImmunoTech	0	0	0	0	N/A

Monte Rosa Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 165.70%. Given Monte Rosa Therapeutics’ higher probable upside, research analysts plainly believe Monte Rosa Therapeutics is more favorable than AIM ImmunoTech.

Valuation and Earnings

This table compares Monte Rosa Therapeutics and AIM ImmunoTech’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	N/A	N/A	-$135.35 million	($2.52)	-1.70
AIM ImmunoTech	$200,000.00	101.64	-$28.96 million	($0.64)	-0.62

AIM ImmunoTech has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.

Summary

Monte Rosa Therapeutics beats AIM ImmunoTech on 8 of the 11 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.